Duality Biotherapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

OTCPK:DUTB.F Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
12 Mar 26	SellUS$1,673,477	King Star Med Management Limited	Company	40,000	US$41.84
16 Jan 26	SellUS$6,893,545	Shaoren Zhang	Individual	150,000	US$45.96
12 Jan 26	SellUS$4,529,727	Wen Si	Individual	100,000	US$45.30
28 Nov 25	SellUS$2,699,594	King Star Med Management Limited	Company	60,000	US$44.99
13 Nov 25	SellUS$5,133,791	Morgan Stanley	Company	134,701	US$38.11
17 Oct 25	SellUS$179,737,760	Eli Lilly Investment Consulting (Shanghai) Co., Ltd.	Company	5,030,300	US$35.73
16 Oct 25	SellUS$26,833,659	King Star Med Management Limited	Company	670,000	US$40.05

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of DUTB.F?
Owner Type	Number of Shares	Ownership Percentage
Private Companies	3,973,214	4.44%
Public Companies	4,337,797	4.85%
Individual Insiders	11,751,263	13.1%
General Public	21,718,048	24.3%
Institutions	22,814,968	25.5%
VC/PE Firms	24,820,124	27.8%

Dilution of Shares: DUTB.F only recently listed within the past 12 months

Top Shareholders

Top 25 shareholders own 73.86% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
14.7%	Eli Lilly Investment Consulting (Shanghai) Co., Ltd.	13,152,921	US$605.6m	-27.7%	34.86%
7.31%	Zhongyuan Zhu	6,538,600	US$301.0m	0.59%	no data
7.14%	Xiamen Yinglian Health Industry Investment Management Co., Ltd.	6,387,649	US$294.1m	0%	no data
5.9%	King Star Med Management Limited	5,279,554	US$243.1m	-19.9%	100.0%
4.66%	Wuxi Biologics Healthcare Venture	4,169,643	US$192.0m	0%	100.0%
4.2%	Fei Chen	3,757,440	US$173.0m	0%	no data
3.73%	Sino Biopharmaceutical Limited	3,333,333	US$153.5m	0%	no data
2.8%	Suzhou Oriza Holdings Co., Ltd.	2,507,440	US$115.4m	0%	6.1%
2.52%	Wellington Management Group LLP	2,250,277	US$103.6m	101%	0.02%
2.1%	Green Pine Capital Partners Co., Ltd.	1,878,721	US$86.5m	0%	26.24%
1.92%	Suzhou Huagai Yizhen Equity Investment Partnership (Limited Partnership)	1,715,774	US$79.0m	0%	no data
1.87%	CICC Capital Management Co., Ltd.	1,674,107	US$77.1m	0%	3.79%
1.87%	CICC Private Equity Investment Management Co., Ltd.	1,674,107	US$77.1m	0%	no data
1.87%	Sw Biotech I Lpf	1,674,107	US$77.1m	0%	no data
1.69%	Xiamen Qisheng Venture Capital Co., Ltd.	1,506,696	US$69.4m	0%	100.0%
1.69%	Hangzhou Tailong Venture Capital Partnership Enterprise (L.P.)	1,506,696	US$69.4m	0%	no data
1.35%	Nga Chun Chau	1,205,223	US$55.5m	0%	no data
1.12%	Tasly Pharmaceutical Group Co., Ltd	1,004,464	US$46.2m	0%	23.69%
1.12%	Capital Research and Management Company	1,004,400	US$46.2m	-38.3%	no data
0.93%	Beijing HuaGai Healthcare Investment Management Co., Ltd.	833,333	US$38.4m	0%	88.87%
0.9%	Hankang Capital	803,482	US$37.0m	0%	34.87%
0.7%	Huagai Capital Co., Ltd.	625,000	US$28.8m	0%	35.31%
0.65%	Huagai Sunshine Investment Fund Lp	583,333	US$26.9m	0%	no data
0.64%	Morgan Stanley	572,971	US$26.4m	0%	no data
0.45%	Hankang Capital Management Limited	401,741	US$18.5m	0%	100.0%

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/01/17 20:01
End of Day Share Price	2025/10/20 00:00
Earnings	2025/06/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Duality Biotherapeutics, Inc. is covered by 10 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Qianlan Zhu	CGS International
Lily Wang	CGS International
Lily Wang	China Galaxy International Securities (Hong Kong)